{"schemaVersion":"ready-scan.discovery-surface.v1","id":"urn:readyscan:corpus:buyer-question:mitaky-q125422561-answer-26214215ddf8c57c21c2","key":"buyer_question:mitaky-q125422561-answer-26214215ddf8c57c21c2","kind":"buyer_question","slug":"mitaky-q125422561-answer-26214215ddf8c57c21c2","canonicalUrl":"https://directory.readyscan.ai/corpus/buyer-question/mitaky-q125422561-answer-26214215ddf8c57c21c2","machineUrl":"https://directory.readyscan.ai/discovery/corpus/buyer-question/mitaky-q125422561-answer-26214215ddf8c57c21c2.json","datePublished":"2026-10-22","dateModified":"2026-10-22","materialFingerprint":"fnv1a64:8c0dd976dfaba02e","membershipFingerprint":"fnv1a64:af0e8f8b2978ae51","relatedEntitySlugs":["mitaky-q125422561"],"relatedSurfaceKeys":["buyer_question:mitaky-q125422561-answer-26107b3485ec4b5bed67","buyer_question:mitaky-q125422561-answer-28f405964cfa21435913","buyer_question:mitaky-q125422561-answer-2f098f50ffdc018bbe0f","buyer_question:mitaky-q125422561-answer-67194cec82646f2730c7","buyer_question:mitaky-q125422561-answer-6945ad974130523ec258","buyer_question:mitaky-q125422561-answer-7275a440b0807c7e491f","buyer_question:mitaky-q125422561-answer-818eae6d67e588931a5b","buyer_question:mitaky-q125422561-answer-cf1345e4652cbcc429b6","buyer_question:mitaky-q125422561-answer-d809d3484c64f2e794ea","buyer_question:mitaky-q125422561-answer-dda3088f82f948d44936","buyer_question:mitaky-q125422561-answer-e70565b30a670e9b6dfb","buyer_question:mitaky-q125422561-answer-f89a83fe2fc6d2d3be0c","evidence:mitaky-q125422561"],"sourceIds":["ready-scan-subjects"],"provenance":[{"snapshotId":"mitaky-q125422561-content-65b618f9ad53d651-snapshot","sourceId":"ready-scan-subjects","sourceRecordId":"Q125422561","sourceRevisionId":"Q125422561:content:f666444add2d8b17","sourceContentHash":"fnv1a64:0cde2888f2848a61","recordRevisionId":"Q125422561:content:f666444add2d8b17","recordContentHash":"fnv1a64:5f3bde14b04eee9b","sourceCanonicalUrl":"https://mitaky.co.jp/","sourceModifiedAt":"2026-10-22T11:27:20.950Z","observedOn":"2026-10-22","permission":{"basis":"public_information","evidenceUrl":"https://mitaky.co.jp/"},"attributionUrl":"https://mitaky.co.jp/"}],"quality":{"method":"same_kind_unique_trigram_floor","minimumUniqueTrigramRatio":0.3,"status":"passed"},"title":"Q2. Is immune cell therapy safe?","summary":"Cited source answers across 1 active corpus record.","question":"Q2. Is immune cell therapy safe?","answers":[{"entitySlug":"mitaky-q125422561","entityName":"MITAKY","answer":"“Yes, immune cell therapy is generally safe because it uses the patient’s own immune cells, which eliminates the risk of rejection or severe allergic reactions. The procedures involved, such as blood collection and reinfusion, are minimally invasive.”","sourceUrls":["https://mitaky.co.jp/products-services/japanese-cancer-immune-cell-therapy-immunotherapy/"]}]}